Orthobiologics

Royal Biologics commenced U.S. commercial launch of Maxx Ultra Cord, a maximum natural thickness allograft derived from umbilical cord....

TheraCell announced the delivery of over 12,000 of its licensed novel demineralized bone fiber products, primarily for use in spinal fusions....

The first 30 patients received treatment in DiscGenics' first-in-human U.S. clinical study of IDCT injectable disc cell therapy for mild to...

Cellular Biomedicine launched a Phase II clinical trial for AlloJoin® allogenic mesenchymal progenitor cell therapy in the treatment of knee osteoarthritis....

Isto Biologics launched Influx Demineralized Bone Matrix Putty, a pre-hydrated graft that is ready to use directly out of the package....

Biogennix received FDA 510(k) clearance and commenced launch of Agilon collagen-enhanced bone graft material....

DiscGenics was granted Fast Track designation from FDA for its investigational cell therapy, IDCT, under evaluation in clinical trials in...

Bioventus is launching its single-injection DUROLANE SJ hyaluronic acid-based OA treatment and received expanded indications for DUROLANE in Australia and New...

Anika Therapeutics announced completion of the first human surgical procedure with the company's injectable HA-based therapy to treat bone voids and defects....

Camber Spine is offering SCYLLA, an allogeneic bone matrix product containing viable spine-derived cells that is complementary to its SPIRA® and ENZA®...